The Relationship of Hemoglobin A1c and Diabetic Wound Healing

NCT ID: NCT01350102

Last Updated: 2017-12-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic wound healing. Additionally, a comparison of two wound dressings, AmeriGel® (Amerx Health Care Corp., Clearwater, FL) and Bacitracin, with and without vitamin C supplementation, will be done to evaluate impact on time to wound closure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective randomized controlled study evaluating the relationship of hemoglobin A1c in diabetic wound healing. Length of time for wound closure will be compared using four treatment options.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes, Type 1 Diabetes, Type 2 Foot Ulcer, Diabetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bacitracin wound care dressing alone

Bacitracin wound care dressing alone

Group Type ACTIVE_COMPARATOR

Bacitracin

Intervention Type DRUG

Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.

Bacitracin with Vit C

Bacitracin wound care dressing with Vitamin C supplementation

Group Type ACTIVE_COMPARATOR

Bacitracin

Intervention Type DRUG

Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.

Vitamin C

Intervention Type DIETARY_SUPPLEMENT

Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve

AmeriGel® wound care dressing alone

AmeriGel® wound care dressing alone

Group Type ACTIVE_COMPARATOR

AmeriGel®

Intervention Type DRUG

Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

AmeriGel® with Vit C

AmeriGel® wound care dressing with Vitamin C supplementation

Group Type ACTIVE_COMPARATOR

AmeriGel®

Intervention Type DRUG

Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

Vitamin C

Intervention Type DIETARY_SUPPLEMENT

Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bacitracin

Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.

Intervention Type DRUG

AmeriGel®

Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

Intervention Type DRUG

Vitamin C

Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Baciguent Oakin®-based hydrogel hydrogel containing Oakin® Oak extract ascorbic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years of age
* Diabetic (Type I and Type II)
* Ulceration of the foot at least one centimeter in width/length
* Ulceration at least 0.2 centimeters in depth

Exclusion Criteria

* Ulceration width/length \> 7.5 centimeters
* Wound depth \> 1.25 centimeters
* Purulent, excessive drainage and/or other signs of infection (i.e. erythema, edema, warmth)
* Inability to provide informed consent
* Inability to swallow pills (vitamin C supplement)
* Patients with concurrent renal problems
* Patients with medication contraindications to Vitamin C and/or topical wound dressings
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Susan Hassenbein

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Susan Hassenbein

Clinical Research Associate

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nell V. Blake, DPM

Role: PRINCIPAL_INVESTIGATOR

Milton S. Hershey Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Markuson M, Hanson D, Anderson J, Langemo D, Hunter S, Thompson P, Paulson R, Rustvang D. The relationship between hemoglobin A(1c) values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care. 2009 Aug;22(8):365-72. doi: 10.1097/01.ASW.0000358639.45784.cd.

Reference Type BACKGROUND
PMID: 19638800 (View on PubMed)

Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations. A controlled, randomized comparison of two moist wound healing protocols: Carrasyn Hydrogel Wound dressing and wet-to-moist saline gauze. Adv Wound Care. 1998 Nov-Dec;11(7 Suppl):1-4. No abstract available.

Reference Type BACKGROUND
PMID: 10326334 (View on PubMed)

Storm DR. Mechanism of bacitracin action: a specific lipid-peptide interaction. Ann N Y Acad Sci. 1974 May 10;235(0):387-98. doi: 10.1111/j.1749-6632.1974.tb43278.x. No abstract available.

Reference Type BACKGROUND
PMID: 4368896 (View on PubMed)

Falabella A, Falanga V. Uncommon causes of ulcers. Clin Plast Surg. 1998 Jul;25(3):467-79.

Reference Type BACKGROUND
PMID: 9696906 (View on PubMed)

Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol. 1994 Apr;130(4):489-93.

Reference Type BACKGROUND
PMID: 8166487 (View on PubMed)

Maklebust JA, Margolis D. The goodness of measurement. Adv Wound Care. 1996 May-Jun;9(3):6. No abstract available.

Reference Type BACKGROUND
PMID: 8716267 (View on PubMed)

van Rijuswijl L. Wound assessment and documentation. In: Krasner LD, Rodeheaver GT, Sibbald RG (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, 3rd ed. Wayne Pa: HMP Communications: 2001;101-115.

Reference Type BACKGROUND

Keast DH, Bowering CK, Evans AW, Mackean GL, Burrows C, D'Souza L. MEASURE: A proposed assessment framework for developing best practice recommendations for wound assessment. Wound Repair Regen. 2004 May-Jun;12(3 Suppl):S1-17. doi: 10.1111/j.1067-1927.2004.0123S1.x.

Reference Type BACKGROUND
PMID: 15230830 (View on PubMed)

Haslik W, Kamolz LP, Andel H, Winter W, Meissl G, Frey M. The influence of dressings and ointments on the qualitative and quantitative evaluation of burn wounds by ICG video-angiography: an experimental setup. Burns. 2004 May;30(3):232-5. doi: 10.1016/j.burns.2003.10.016.

Reference Type BACKGROUND
PMID: 15082349 (View on PubMed)

Droog EJ, Steenbergen W, Sjoberg F. Measurement of depth of burns by laser Doppler perfusion imaging. Burns. 2001 Sep;27(6):561-8. doi: 10.1016/s0305-4179(01)00021-3.

Reference Type BACKGROUND
PMID: 11525849 (View on PubMed)

Duckworth WC, Fawcett J, Reddy S, Page JC. Insulin-degrading activity in wound fluid. J Clin Endocrinol Metab. 2004 Feb;89(2):847-51. doi: 10.1210/jc.2003-031371.

Reference Type BACKGROUND
PMID: 14764804 (View on PubMed)

Zimny S, Schatz H, Pfohl M. Determinants and estimation of healing times in diabetic foot ulcers. J Diabetes Complications. 2002 Sep-Oct;16(5):327-32. doi: 10.1016/s1056-8727(01)00217-3.

Reference Type BACKGROUND
PMID: 12200075 (View on PubMed)

Rubinstein A, Pierce CE Jr. Rapid healing of diabetic foot ulcers with meticulous blood glucose control. Acta Diabetol Lat. 1988 Jan-Mar;25(1):25-32. doi: 10.1007/BF02581242.

Reference Type BACKGROUND
PMID: 3043987 (View on PubMed)

Yue DK, McLennan S, Marsh M, Mai YW, Spaliviero J, Delbridge L, Reeve T, Turtle JR. Effects of experimental diabetes, uremia, and malnutrition on wound healing. Diabetes. 1987 Mar;36(3):295-9. doi: 10.2337/diab.36.3.295.

Reference Type BACKGROUND
PMID: 3803737 (View on PubMed)

Vitamin C and the common cold. Med Lett Drugs Ther. 1970 Dec 25;12(26):105-6. No abstract available.

Reference Type BACKGROUND
PMID: 4936077 (View on PubMed)

Howe GR, Hirohata T, Hislop TG, Iscovich JM, Yuan JM, Katsouyanni K, Lubin F, Marubini E, Modan B, Rohan T, et al. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst. 1990 Apr 4;82(7):561-9. doi: 10.1093/jnci/82.7.561.

Reference Type BACKGROUND
PMID: 2156081 (View on PubMed)

Wassertheil-Smoller S, Romney SL, Wylie-Rosett J, Slagle S, Miller G, Lucido D, Duttagupta C, Palan PR. Dietary vitamin C and uterine cervical dysplasia. Am J Epidemiol. 1981 Nov;114(5):714-24. doi: 10.1093/oxfordjournals.aje.a113243.

Reference Type BACKGROUND
PMID: 7304600 (View on PubMed)

Snyder RJ, Kirsner RS, Warriner RA 3rd, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010 Apr;56(4 Suppl):S1-24.

Reference Type BACKGROUND
PMID: 20424290 (View on PubMed)

Pollack SV. Wound healing: a review. III. Nutritional factors affecting wound healing. J Dermatol Surg Oncol. 1979 Aug;5(8):615-9. doi: 10.1111/j.1524-4725.1979.tb00733.x.

Reference Type BACKGROUND
PMID: 479447 (View on PubMed)

van Anholt RD, Sobotka L, Meijer EP, Heyman H, Groen HW, Topinkova E, van Leen M, Schols JM. Specific nutritional support accelerates pressure ulcer healing and reduces wound care intensity in non-malnourished patients. Nutrition. 2010 Sep;26(9):867-72. doi: 10.1016/j.nut.2010.05.009. Epub 2010 Jul 3.

Reference Type BACKGROUND
PMID: 20598855 (View on PubMed)

Smith RG. Validation of Wagner's classification: a literature review. Ostomy Wound Manage. 2003 Jan;49(1):54-62.

Reference Type BACKGROUND
PMID: 12532034 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-35832

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stretching and Diabetes
NCT06774105 COMPLETED NA
Renal Denervation in Diabetes.
NCT02081989 WITHDRAWN PHASE4